Lexeo Therapeutics, Inc. has announced the pricing of its underwritten public offering and concurrent private placement, with gross proceeds of approximately $135 million. The public offering included 15,625,015 shares of common stock at an offering price of $8.00 per share, with an option for underwriters to purchase up to an additional 2,343,750 shares. Concurrently, the company has agreed to sell pre-funded warrants to purchase 1,250,000 shares of common stock in a private placement.
The offering is expected to close on or about October 20, 2025, subject to customary closing conditions. Leerink Partners, Cantor, Stifel, and Oppenheimer & Co. are acting as joint book-running managers for the public offering, while Baird is serving as the lead manager. Leerink Partners also served as the sole placement agent for the concurrent private placement.
Lexeo Therapeutics is a clinical stage genetic medicine company focused on developing treatments for cardiovascular diseases. The company's portfolio includes therapeutic candidates targeting genetic causes of conditions such as Friedreich ataxia (FA) cardiomyopathy and plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy.
The specific figures from the press release are the gross proceeds of approximately $135 million from the public offering and concurrent private placement, the offering price of $8.00 per share for the public offering, and the number of shares and pre-funded warrants offered by Lexeo Therapeutics. These metrics highlight the financial aspects of the company's recent funding activities and its efforts to advance its therapeutic candidates. The market has reacted to these announcements by moving the company's shares 9.24% to a price of $9.58. Check out the company's full 8-K submission here.
